Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-03-03 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第四届董事会第四十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 健帆生物科技集团股份有限公司. It details the convening of the board meeting, attendance, and the approval of a specific agenda item related to the cancellation of certain restricted shares. The document includes voting results and references compliance with company law and internal regulations. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is not an annual or interim report, nor an earnings release. The content is focused on board decisions and management actions, specifically about share incentives and board resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not merely announcing a report publication but is itself the announcement of a board decision.
2023-03-03 Chinese
国浩律师（深圳）事务所关于健帆生物科技集团股份有限公司作废部分已授予尚未归属的第二类限制性股票之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain unvested restricted shares under a 2021 restricted stock incentive plan of the company. It discusses approvals, authorizations, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is a legal opinion related to corporate governance and stock incentive plan adjustments, not a financial report or announcement of voting results. It is not a report publication announcement since it contains substantive legal analysis and conclusions. The document fits best under Regulatory Filings (RNS) as it is a legal compliance document related to corporate stock incentive matters and does not fit other more specific categories.
2023-03-03 Chinese
关于作废部分已授予尚未归属的第二类限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of certain unvested restricted stock awards under a 2021 stock incentive plan. It details board and supervisory meetings, legal opinions, and the rationale for the cancellation of these shares. The content focuses on corporate governance and management decisions related to equity incentives, rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full annual or interim report, nor an earnings release or call transcript. It is also not a proxy solicitation or voting results announcement. The document is a formal disclosure about management decisions on stock incentives, which fits best under Board/Management Information (MANG) as it relates to management actions and board resolutions on equity awards.
2023-03-03 Chinese
关于公司技术中心被认定为国家企业技术中心的自愿性披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company about its technology center being recognized as a National Enterprise Technology Center. It includes no financial statements, no detailed financial data, no regulatory certifications, or voting results. It is a regulatory announcement about a recognition event, not a report or detailed financial filing. The document length is short (658 characters), and it is an announcement of a recognition event, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-03-01 Chinese
关于部分股票期权注销完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of certain stock options by the company. It details the number of stock options cancelled, reasons for cancellation such as employee departure and performance, and confirms that the cancellation does not affect the company's share capital. There is no indication of financial statements, audit information, or detailed financial performance. The document is a corporate announcement about stock option cancellations, which relates to changes in capital structure but specifically about stock options being cancelled rather than new share issues or repurchases. This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding capital changes including stock options and related adjustments.
2023-02-09 Chinese
第四届监事会第四十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the cancellation of certain stock options. It includes details about the meeting attendance, the agenda, and voting results. The content focuses on corporate governance and internal decisions related to stock option plans, not on financial results, audit opinions, or regulatory filings. The document length is short (1090 characters), and it is an announcement of a board resolution rather than a full report or financial statement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2023-02-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.